A phase III trial, combining the IGF-1R inhibitor dalotuzumab with cetuximab, showed numerically superior PFS and OS improvement in patients with CRC with IGF-1R-positive tumors,150 although preclinical studies did not support noticeable benefits from anti-IGF-1R treatment,151 which implied that more steps are needed for IGF-1R targeting. The gene discussed is IGF1R; the disease is colorectal carcinoma.